SHIFA BIOMEDICAL CORPORATION

Shifa Biomedical Corporation is a preclinical-stage biopharmaceutical company developing orally bioavailable small molecule drugs targeting PCSK9 to lower LDL cholesterol and reduce cardiovascular disease risk. The company's lead compound P-21 has demonstrated potency comparable to injectable monoclonal antibodies while offering the convenience of oral administration — a potential first-in-class approach. Shifa has received SBIR funding from the Department of Health and Human Services.